Selective use of vandetanib in the treatment of thyroid cancer

Vandetanib is a once-daily orally available tyrosine kinase inhibitor that works by blocking RET (REarranged during Transfection), vascular endothelial growth factor receptor (VEGFR-2, VEGFR-3), and epidermal growth factor receptor and to a lesser extent VEGFR-1, which are important targets in thyro...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Drug Des Devel Ther
Auteurs principaux: Fallahi, Poupak, Di Bari, Flavia, Ferrari, Silvia Martina, Spisni, Roberto, Materazzi, Gabriele, Miccoli, Paolo, Benvenga, Salvatore, Antonelli, Alessandro
Format: Artigo
Langue:Inglês
Publié: Dove Medical Press 2015
Sujets:
Review
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4498730/
https://ncbi.nlm.nih.gov/pubmed/26170630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S72495
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires